The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Open accessAbstract
OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. RESULTS: Thirty-four studies met inclusion criteria; 8 were rated as Class I. CONCLUSIONS: The following were studied in patients with MS: (1) Spasticity: oral cannabis extract (OCE) is effective, and nabiximols and tetrahydrocannabinol (THC) are probably effective, for reducing patient-centered measures; it is possible both OCE and THC are effective for reducing both patient-centered and objective measures at 1 year. (2) Central pain or painful spasms (including spasticity-related pain, excluding neuropathic pain): OCE is effective; THC and nabiximols are probably effective. (3) Urinary dysfunction: nabiximols is probably effective for reducing bladder voids/day; THC and OCE are probably ineffective for reducing bladder complaints. (4) Tremor: THC and OCE are probably ineffective; nabiximols is possibly ineffective. (5) Other neurologic conditions: OCE is probably ineffective for treating levodopa-induced dyskinesias in patients with Parkinson disease. Oral cannabinoids are of unknown efficacy in non-chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy. The risks and benefits of medical marijuana should be weighed carefully. Risk of serious adverse psychopathologic effects was nearly 1%. Comparative effectiveness of medical marijuana vs other therapies is unknown for these indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-25028 · Cited by 256
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., & Gouaux, B. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110837 · Cited by 235
Cited by
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Abrams, D. I. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.003 · Cited by 296
Positive and Negative Effects of Cannabis and Cannabinoids on Health
Cohen, K., Weizman, A., & Weinstein, A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1381 · Cited by 255
Beyond THC and Endocannabinoids
Pacher, P., Kogan, N. M., & Mechoulam, R. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021441 · Cited by 175
Häuser, W., Petzke, F., & Fitzcharles, M. A. (2018) · European Journal of Pain · doi:10.1002/ejp.1118 · Cited by 175
Bradford, A. C., & Bradford, W. D. (2017) · Health Affairs · doi:10.1377/hlthaff.2016.1135 · Cited by 172
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166
Nielsen, S., Germanos, R., Weier, M., Pollard, J., Degenhardt, L., Hall, W., Buckley, N., & Farrell, M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0814-x · Cited by 153
Therapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01880-2 · Cited by 139
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30406-x · Cited by 104
Petzke, F., Enax-Krumova, E. K., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0089-y · Cited by 80
Shkodina, A. D., Bardhan, M., Chopra, H., Anyagwa, O. E., Pinchuk, V. A., Hryn, K. V., Kryvchun, A. M., Boiko, D. I., Suresh, V., Verma, A., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01072-5 · Cited by 31
Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006–2015
Maloney-Hall, B., Wallingford, S. C., Konefal, S., & Young, M. M. (2020) · Health Promotion and Chronic Disease Prevention in Canada · doi:10.24095/hpcdp.40.5/6.06 · Cited by 21
De Luca, C., Buratti, A., Krauke, Y., Stephan, S., Monks, K., Brighenti, V., Pellati, F., Cavazzini, A., Catani, M., & Felletti, S. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03862-y · Cited by 18
Metadata
- Venue
- Neurology
- Published
- 2014-04-29
- Volume
- 82
- Issue
- 17
- Pages
- 1556-1563
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2096621017
- Cited by
- 553
- References
- 10
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
